Biovail Fires Back At AstraZeneca In Seroquel IP Suit
Biovail Corp. has become the latest generics maker to ask a court to invalidate or rule unenforceable two patents for Seroquel XR — AstraZeneca Pharmaceuticals LP's popular treatment for bipolar disorder...To view the full article, register now.
Already a subscriber? Click here to view full article